Plancorp LLC Sells 1,287 Shares of Eli Lilly and Company $LLY

Plancorp LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 10.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,546 shares of the company’s stock after selling 1,287 shares during the quarter. Plancorp LLC’s holdings in Eli Lilly and Company were worth $8,810,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $27,000. Sumitomo Mitsui Financial Group Inc. bought a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. purchased a new position in Eli Lilly and Company during the second quarter valued at approximately $29,000. Steph & Co. raised its stake in Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares in the last quarter. Finally, Financial Gravity Companies Inc. purchased a new stake in Eli Lilly and Company during the second quarter worth $31,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LLY. BMO Capital Markets set a $1,200.00 price target on Eli Lilly and Company in a report on Thursday, December 4th. HSBC reaffirmed a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Finally, Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,155.36.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,077.06 on Thursday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99. The company has a market cap of $1.02 trillion, a PE ratio of 52.69, a P/E/G ratio of 1.08 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The business has a 50-day simple moving average of $976.10 and a two-hundred day simple moving average of $837.36.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Positive clinical data and pipeline momentum: MarketBeat and other coverage highlight strong orforglipron (oral) maintenance data and very high-weight-loss results for retatrutide, supporting Lilly’s 2026 outlook and the potential for new, recurring revenue streams if approvals succeed. (Pipeline upside is a major growth driver.)
• Positive Sentiment: Analysts raising estimates: Zacks and other outlets have lifted near‑term EPS estimates for Lilly, indicating improving sell‑side expectations for upcoming quarters — a supportive signal for valuation and sentiment.
• Positive Sentiment: Breast‑cancer trial update adds diversification to growth story: Lilly announced updated meaningful data on a breast cancer treatment, which could broaden the company’s revenue base beyond GLP‑1s and reduce single‑product risk. Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment
• Neutral Sentiment: Stock‑split speculation: Commentary that LLY is a top stock‑split candidate in 2026 may boost retail interest and liquidity if management acts, but it is not a fundamental earnings catalyst on its own. Eli Lilly (LLY) a Top Stock Split Candidate in 2026
• Neutral Sentiment: Technical/band commentary: Some technical analysts are flagging buy zones and short‑term ranges for LLY, which can influence short‑term trading flows but not fundamentals. Eli Lilly & Company (LLY): Buyers looking for rally between $1144.4 – $1196.17
• Neutral Sentiment: M&A interest in niche assets: Analysis suggesting Lilly might target small biotech assets (e.g., Abivax) is speculative — could be accretive but not immediate. Abivax: Here’s Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
• Negative Sentiment: Competitive pressure from Novo Nordisk’s newly FDA‑approved oral Wegovy pill: Novo’s approval and planned U.S. launch (early January) has pushed investors to re‑rate competitive dynamics in the obesity/GLP‑1 market — a near‑term headwind for Lilly’s market share and pricing expectations. Focus: Lilly, Novo lock horns in India’s obesity drug race
• Negative Sentiment: India and generics risk: Reports that Lilly and Novo are racing to capture India’s obesity market ahead of cheaper generics due in March raise margin and volume risks in a large market — increased competition can pressure growth forecasts. Eli Lilly and Novo Nordisk Battle for India’s Fast‑Growing Obesity‑Drug Market
• Negative Sentiment: Analyst downgrade / cautionary market commentary: A recent Seeking Alpha piece downgraded the stock, reflecting concerns about valuation, tolerability issues for next‑gen drugs (discontinuation rates), and near‑term competitive threats — a sentiment headwind for momentum investors. Eli Lilly: Mr. Market Finally Woke Up, But I’m Not Out Yet (Rating Downgrade)

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.